Intermittent Fasting Fights Cancer Through Multiple Molecular Pathways

Cancer remains a leading cause of global mortality, and conventional therapies carry significant toxicity and cost burdens. Dietary interventions like intermittent fasting (IF) have emerged as potentially powerful adjuncts to standard oncology care, and this 2026 review by Abdalla et al. provides a comprehensive synthesis of the molecular and clinical evidence supporting IF's anticancer role.

The review's central thesis is that IF operates through both autophagy-dependent and autophagy-independent mechanisms. Autophagy—the lysosomal degradation pathway that clears damaged organelles and oncogenic proteins—is activated during fasting and can suppress tumor initiation. Independently, IF also suppresses insulin and IGF-1 signaling, which drives the PI3K/Akt/mTOR axis commonly dysregulated in malignancy. By reducing circulating insulin and IGF-1 (documented in human Ramadan fasting studies), IF reverses the Warburg effect—where cancer cells preferentially use glycolysis—and pushes tumor cells toward less efficient oxidative phosphorylation, increasing apoptosis. Preclinical colorectal cancer models confirmed increased oxygen consumption and decreased ATP production in tumor tissue under fasting conditions.

IF also remodels the immune landscape. It transiently depletes circulating leukocytes followed by hematopoietic stem cell-driven immune regeneration, yielding enhanced cytotoxic T lymphocyte and natural killer cell activity. In murine models, IF reprogrammed NK cell metabolism to improve survival and cytotoxicity within the tumor microenvironment. Anti-inflammatory effects—reductions in IL-6, TNF-α, IL-1β, and CRP—were consistently observed in human fasting protocols exceeding 48 hours, mediated via NF-κB suppression and AMPK activation.

Gut microbiota remodeling represents another axis: IF increases anti-inflammatory species like Akkermansia muciniphila and Bifidobacterium, boosting short-chain fatty acid production (butyrate, propionate) that inhibits tumor growth via histone deacetylase inhibition. IF also remodels the bile acid pool to activate farnesoid X receptor, which exerts antiproliferative effects in hepatocellular and colorectal cancer models. Epigenetically, fasting activates sirtuins 1 and 6, which silence oncogenes through histone modification and DNA methylation changes. Finally, IF restores circadian clock gene expression (BMAL1, PER2, CLOCK), which are increasingly recognized as tumor suppressors whose disruption promotes carcinogenesis.

Clinically, IF's 'differential stress resistance' phenomenon is particularly actionable: cancer cells under metabolic stress show reduced DNA repair and heightened chemosensitivity, while normal cells enter protective quiescence, reducing off-target toxicity. In breast cancer patients, an 18-hour fasting window around chemotherapy cycles prevented insulin and glucose spikes seen in non-fasting patients, correlating with reduced toxicity. Multiple clinical trials in breast, ovarian, and colorectal cancers are now investigating fasting-chemotherapy combinations. A trial combining fasting-mimicking diet with ketogenic diet in breast cancer patients showed enhanced AMPK activation and reduced tumor biomarkers.